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Abstract  
 
Purpose of review  
There are over 100 serotypes of human enteroviruses, which cause a spectrum of 
illnesses, including meningitis, encephalitis, paralysis, myocarditis and rash. 
Increasing incidence of hand-foot-and-mouth disease in the Asia-Pacific and recent 
outbreaks of enterovirus-associated disease, such as severe respiratory illness in the 
United States in 2014, highlight the threat of these viruses to human health.  
 
Recent findings  
We describe recent outbreaks of human enteroviruses and summarise knowledge 
gaps regarding their burden, spectrum of diseases and epidemiology.  
 
Summary  
Reported outbreaks of respiratory, neurological, skin and eye diseases associated 
with human enteroviruses have increased in frequency and size in recent years. 
Improved molecular diagnostics and genetic sequence analysis are beginning to 
reveal the complex dynamics of individual serotypes and genotypes, and their 
contribution to these outbreaks. However, the biological mechanisms underlying their 
emergence and transmission dynamics remain elusive. They are likely to involve 
changes in the virus, such as fitness, antigenicity, virulence or tropism, and in the 
human population, such as levels of sanitation and of homo- and heterotypic 
immunity. Improvements in surveillance, serological surveys and detailed genetic 
and antigenic characterisation of viral populations would help to elucidate these 
mechanisms. This will be important for the design of outbreak control and vaccine 
development strategies. 
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Introduction 
 
Enteroviruses (EVs, Picornaviridae family) are a genus of small, non-enveloped, 
single-stranded RNA viruses. They have high mutation rates and undergo frequent 
recombination. The genome region encoding their capsid protein VP1 (which 
contains the majority of neutralization epitopes) correlates well with serotypes and 
molecular methods use it for serotyping [1]. Molecular typing has largely replaced 
neutralization tests and is now considered the gold standard. More than 100 
enterovirus serotypes infect humans, and are currently classified into four species, A 
to D, according to molecular and antigenic properties (Table 1, Figure 1). This large 
group of viruses includes polioviruses, coxsackieviruses A and B, echoviruses, and 
various serotypes identified more recently simply called “enterovirus” and 
sequentially numbered (starting at 68).  
 
Most human enteroviruses enter the body via the alimentary or respiratory tract and 
spread by both fecal-oral and respiratory routes, although a few exceptions to the 
usual modes of transmission exist [2]. Rhinoviruses, which are closely related to 
enteroviruses, have recently been classified within the genus Enterovirus, but they 
have unique biological and physical properties that cause them to be restricted to the 
upper respiratory tract [2]. Rhinoviruses are beyond the scope of this review, as are 
polioviruses, which are the target of a major eradication initiative. 
 
Enterovirus infections can result in a wide range of clinical diseases, from minor 
febrile illness and rash to severe, sometimes fatal, conditions, including meningitis, 
encephalitis, paralysis and myocarditis (Table 2). Although most infections are 
subclinical, sporadic or regular outbreaks of disease are common worldwide, and can 
lead to significant morbidity and mortality. In particular, non-polio enteroviruses are 
recognised as an emerging cause of neurological diseases, which more often arise 
as complications of mild infections. This has become more evident during recent 
years. For example, hand-foot-and-mouth disease (caused by EV-A71 and CV-A16, 
among others) has been increasing in incidence in the Asia-Pacific, and despite polio 
having been eliminated from most countries, the burden of acute flaccid paralysis 
(AFP) remains high, with many of those cases associated with non-polio 
enteroviruses [3].  
 
Enteroviruses often show seasonal patterns of incidence in both temperate and 
tropical climates, although seasonality is typically more marked in the former, with 
infections more common in summer and early autumn [2]. Passive laboratory 
surveillance of clinical isolates reveals different patterns of circulation over time and 
by geographic location for individual serotypes. For example, surveillance in the USA 
[4] recorded large and periodic outbreaks followed by years of relative quiescence for 
some serotypes (e.g. echovirus 9 exhibits large outbreaks every 3–5 years), whilst 
other serotypes have endemic patterns with relatively stable circulation (e.g. 
coxsackievirus B4), and others irregular patterns (Figure 2). 
 
Enterovirus surveillance relies on passive, voluntary, laboratory-based systems, 
where participating laboratories report enterovirus detection to a reference centre 
(e.g. in the USA, the UK, the Netherlands, France [4,5,6,7]). Although enterovirus 
surveillance may in theory provide information relevant to the detection of outbreaks 
and changing patterns of infection, the burden of disease and the emergence of new 
strains, in practice these systems suffer a number of important biases. First, most 
enterovirus-associated diseases are not notifiable (except AFP), such that only a 
small proportion of all cases of a clinical illness are tested. Second, methods for virus 
identification have changed during the last decade (cell culture has been superseded 
by molecular methods). Third, an increasing number of enterovirus-positive 
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specimens remain untyped because many laboratories do not perform molecular 
typing and samples may not be submitted to reference centres with this capacity. 
Fourth, laboratory methods used to test specimens are not standardised (e.g. use of 
different primers). Finally, in a context of an outbreak, the number of reports is likely 
to increase due to enhanced surveillance.  
 
Recent outbreaks of disease, such as hand-foot-and-mouth disease (HFMD) in the 
Asia-Pacific and the outbreak of severe respiratory illnesses (caused by EV-D68) last 
year in the USA [8,9], have raised basic and applied questions about the 
mechanisms determining their emergence and transmission dynamics. Here, we 
review the epidemiology of recent outbreaks, progress towards the development of 
vaccines to control such outbreaks, and outstanding research questions that are 
important from a public health perspective.  
 
 
Outbreak of severe respiratory illness in the USA in 2014  
 
Enterovirus D68 (EV-D68) has biological features similar to rhinoviruses (e.g. acid 
lability and optimal growth at 33ºC [10]) and has long been exclusively associated 
with respiratory diseases. First isolated in 1962 from four children with pneumonia 
and bronchiolitis in California [11], only sporadic cases were reported until the late 
2000s. In the USA, only 26 cases were notified between 1970 and 2005 [4].  
 
During the last decade, several clusters of relatively small size (no more than 40 
cases) of respiratory illnesses associated with EV-D68 occurred in Asia [12,13,14,15], 
Europe [12,16,17] and the USA [12,18], mostly affecting young children aged 0–4 
years. The clinical respiratory manifestations ranged from mild to severe, sometimes 
fatal. Most clusters showed an atypical late seasonality compared to other 
enteroviruses with a peak in autumn, instead of summer [12]. The apparent increase 
in the number of detections was first thought to be related to improvements in 
detection techniques, since older tests could not detect EV-D68 or misidentified it as 
a rhinovirus [12]. However, retrospectively tested samples from the Netherlands and 
Japan confirmed the increase [13,16], which was also accompanied by an expansion 
in genetic diversity in the late 2000s [16,19]. Currently, three co-circulating clades of 
EV-D68 have been described, which probably diversified during the mid to late 1990s 
[13,16,19]. These clades have recently been shown to have different antigenic 
properties [20*].  
 
A number of biological mechanisms have been hypothesized for the observed global 
increase in EV-D68 detections over the last decade. For example, amino acid 
changes in the VP1 compared to the Fermon reference strain that have resulted in 
altered antigenic properties may have permitted immune escape [16,20*]. 
Alternatively, EV-D68 may have become more virulent as a result of nucleotide 
deletions in the 5’ untranslated region [19].  
 
In 2014, the largest outbreak to date of severe respiratory illness associated with EV-
D68 occurred in the USA. The first cases were reported in August 2014 from 
Missouri and Illinois, and by January 2015 more than 1,150 cases across the country 
had been confirmed [8,9]. Of note, almost all the cases were children and a 
considerable proportion had a previous history of asthma or wheezing [8,9].  
 
Coinciding with the 2014 outbreak in the USA, there was an unusual number of 
reports of children who developed a sudden onset of acute weakness in arms or legs 
similar to that caused by polioviruses; this is now referred to as acute flaccid myelitis 
(AFM) [21]. The first cluster was reported in Colorado, started in August 2014 and 
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involved 12 children [22,23]. The total number of AFM reports by mid-April 2015 was 
118 from 34 states in the USA and most cases were children <18 years of age 
[21,24]. Interestingly, during the two years preceding the EV-D68 outbreak, an 
unusual number (23 in total) of “polio-like” illness were also reported in California [25], 
among which some had a clinical and radiologic picture similar to the AFM cases 
described since August 2014 [25]. Most AFM patients reported a respiratory and/or 
febrile illness preceding the onset of the neurological symptoms [22,24] and some 
tested positive for EV-D68 in nasopharyngeal samples (5/11 in Colorado [22], 8/41 
tested at CDC [24], 2/23 in California [25]). Although the virus has not been detected 
in the CSF of patients [22,24] (in fact, EV-D68 has only been isolated from CSF in 
two cases in the literature, once in 2005 [4] and once in 2008 [26]), these 
observations raised the question of an association between the outbreak of EV-D68 
respiratory disease and those cases of neurologic illness. A new phylogenetic study 
has strengthened that putative association [27*]. It showed that EV-D68 strains from 
AFM cases belonged to a recent evolutionary cluster, clade B1, which emerged in 
2010. The same study identified six single nucleotide polymorphisms (SNPs) specific 
to clade B1, some of which matched with SNPs in polioviruses and enterovirus D70 
(which has previously been linked with AFP) and might have conferred 
neurovirulence to EV-D68 [27*].  
 
 
Large-scale epidemics of acute haemorrhagic conjunctivitis 
 
Two enteroviruses are the main etiological agents of explosive and large-scale 
outbreaks of acute haemorrhagic conjunctivitis (AHC): enterovirus D70 (EV-D70) and 
an antigenic variant of coxsackievirus A24 (CV-A24v). Both strains spread mainly via 
direct or indirect contact with eye secretions and both have been found in stool, 
suggesting that the fecal-oral route is also a mode of transmission [28,29]. A tropism 
of CV-A24v for the airways has also been suggested, which makes respiratory 
transmission also likely [30]. Although most cases resolve without sequelae after a 
5–7 day course, microbial superinfection can occur and neurological complications 
such as “polio-like” paralysis have been reported during AHC outbreaks of EV-D70 
[29,31]; however, the virus was not isolated from CSF [29,31] and cases were 
reported from settings where polio was still endemic, leaving the causal link uncertain.  
 
The first documented outbreak of AHC due to EV-D70 occurred in Ghana in 1969 
[32,33], and during 1970 and 1971 the virus spread globally, producing the first AHC 
pandemic and affecting millions of people [33,34]. Since the mid-1990s, no more 
outbreaks due to EV-D70 have been documented [35,36,37]. 
 
CV-A24v was first isolated in 1970 in Singapore [38] and remained restricted to 
South-East Asia and India until 1985. Since then, it has been responsible for 
outbreaks worldwide (e.g. Cuba 2008–2009 [28]; China 2010 [39]; India 2010 [40]; 
Japan 2011 [41]; Thailand 2014 [42]), including two pandemics: the first started in 
1985 [43,44] and the second in 2002 [45]. Phylogenetic analyses of CV-A24v 
allowed the identification of four genotypes (GI to GIV): GI and GII included isolates 
from the 1970s, GIII from the late 1980s and early 1990s (i.e. including the first 
pandemic), and GIV from the second pandemic and others more recently identified 
[28,39,40,42,46,47]. This suggests a turnover of CV-A24v genotypes: new genetic 
variants rapidly spread globally and then fade out to be replaced by new variants.  
 
With some exceptions, outbreaks of AHC seem to principally affect tropical and 
subtropical regions during the hot, rainy seasons and some countries have 
experienced several outbreaks during the last decades (e.g. Singapore, Thailand, 
Brazil, China, India). A recent study from Thailand suggests that CV-A24v has been 
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continuously circulating at least since 2002, producing large and periodic epidemics 
every 2–3 years interspersed with minor outbreaks and sporadic cases [42]. Older 
studies showed that infected individuals develop neutralizing antibodies that last only 
for a few years [48,49], which could explain the patterns observed in Thailand, where 
extensive outbreaks may occur when population immunity falls below a certain 
threshold.  
 
The size of AHC outbreaks and their rapid spread impose a significant burden on 
primary healthcare systems and normal activities of affected countries may be partly 
paralyzed (e.g. schools, companies, sports) [50]. Because no treatment (either 
vaccines or antiviral drugs) is currently available, control measures are reduced to 
limiting the spread of the virus (e.g. encouraging hand-washing and increased 
hygiene, and alerts via radio and media channels).  
 
 
Hand-foot-and-mouth disease in the Asia-Pacific region 
 
Hand-foot-and-mouth disease (HFMD) is a common, typically mild and self-limiting 
illness that mainly affects young children under 5 years of age (clinical manifestations 
include fever, a rash with blisters on hands, feet and buttocks, and vesicles in the 
mouth). The most common etiological agents are enterovirus A71 (EV-A71) and 
coxsackievirus A16 (CV-A16). Approximately 30% of hospitalised HFMD patients 
with EV-A71 infection develop more severe disease including neurological symptoms 
(e.g. aseptic meningitis, encephalitis, acute flaccid paralysis) and cardiopulmonary 
complications [51,52], which in some cases can be fatal. These severe outcomes are 
very unusual with CV-A16 [51]. EV-A71 is currently considered the most neurotropic 
enterovirus beyond polioviruses and there is a considerable literature on it (for 
reviews see [53,54,55]). 
 
Only small outbreaks and sporadic cases of EV-A71 were reported throughout the 
world between the early 1970s and the late 1990s, with the exception of two large 
outbreaks, one in Bulgaria in 1975 [56] and one in Hungary in 1978 [57], both 
associated with a high mortality. During the last 10–20 years, major outbreaks of 
HFMD have occurred in the Asia-Pacific, becoming an important public health 
problem. This has led to increasing attention from health authorities, declaration of 
HFMD as a notifiable disease and the introduction of case-based surveillance 
systems [58]. Unprecedented outbreaks occurred in 1997 in Sarawak, Malaysia (at 
least 34 deaths [59,60]) and in 1998 in Taiwan (total number of cases estimated at 
around 1.5 million, >120,000 cases reported, among which >400 had severe 
diseases and 78 died [60,61]). Large-scale outbreaks have subsequently been 
reported in Malaysia, Taiwan, Singapore, China, Hong Kong, Japan, Republic of 
Korea, Vietnam and Cambodia. In China, from 2008 to 2014, >10 million cases of 
HFMD and >3,000 deaths were reported [62], with 80% of severe cases and 93% of 
fatal cases due to EV-A71 [63**]. 
 
Although outbreaks tend to occur in warmer months, significant geographical 
variability in the epidemic patterns of HFMD has been observed. A study based on 
surveillance data from China showed that the periodicity of the outbreaks and the 
timing of the peak varied with latitude [63**]: northern provinces had one peak in 
June, (as observed in Japan [64]), whereas southern provinces had two peaks, 
around May and October (as observed in the South of Vietnam [65]). Other countries, 
however, such as Hong Kong and Singapore, have observed changes over time in 
the periodicity of the peaks [66,67,68,69]. Although seasonal variation has been 
suggested to be associated with climatic factors [63**], other factors, like changes in 
the circulating and predominant serotypes (some of which could circulate or peak 
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earlier than others) could also be involved (e.g. in Singapore, changes in the 
dominant serotype coincided with changes in the annual number of peaks [66]).  
 
Temporal changes in the circulating and predominant serotypes have been observed 
in many places. For example, EV-A71 seems to have a periodicity of 3–4 years in 
Japan [64], and 3 years in Malaysia [70], whereas in China it circulated widely every 
year from 2008 to 2014 [62,63**]. Coxsackievirus A6 (CV-A6) has become a 
predominant serotype in many places during the last 2 to 5 years, often replacing 
EV-A71 and CV-A16 as the main cause of HFMD: e.g. Japan [64], Singapore [67,68], 
and different regions in China [71,72,73,74,75,76]. In a few places, coxsackievirus 
A10 (CV-A10) has also been recently reported as a predominant serotype [77,78]. 
Some of the CV-A6 and CV-A10 strains currently circulating in the Asia-Pacific are 
likely to have originated in Europe, where they caused outbreaks of atypical HFMD 
(e.g. associated with nail shedding [79,80]).  
 
Concerns that large-scale outbreaks of HFMD may occur in India have arisen, mainly 
because of the close proximity to China and other conditions that could favour the 
rapid spread of the virus, including high population density and poor hygiene and 
sanitation [81]. Nevertheless, only small-scale outbreaks have occurred to date. Why 
the disease seems to be mainly restricted to the Asia-Pacific remains unknown. 
 
HFMD vaccine development 
 
Owing to the growing threat of HFMD in countries in the Asia-Pacific and the lack of 
effective antiviral therapies, efforts to develop an EV-A71 vaccine have recently been 
accelerated. The successful use of inactivated and live-attenuated poliovirus 
vaccines as part of the Global Polio Eradication Initiative emphasizes the potential to 
achieve safe and durable protective immunity against enterovirus infection. A variety 
of EV-A71 vaccine candidates have been evaluated in preclinical studies, including 
inactivated [82], live-attenuated [83], virus-like particle [84], subunit [85], and DNA 
vaccines [85]. Among these, formalin-inactivated whole-virus vaccines are the most 
advanced, and five candidates developed in mainland China, Taiwan and Singapore 
have entered clinical evaluation [86]. Recently, phase III randomized, double-blind, 
placebo-controlled trials were conducted in China for three of these vaccines 
[87,88,89]. Each trial involved the administration of two doses of alum-adjuvant 
inactivated EV-A71 vaccine or placebo at an interval of 28 days to more than 10,000 
children aged 6–35 months [88,89] or 6–71 months [87]. Surveillance for EV-A71-
associated disease (including HFMD, CNS disease and other EV-A71-associated 
sequelae) was then performed for up to 1 year. Each vaccine displayed an 
acceptable safety profile, and protective efficacy against EV-A71-associated HFMD 
ranged between 90.0% and 97.4%, raising the possibility that an EV-A71 vaccine will 
soon be licensed in China.  
 
Despite this recent progress, several hurdles to the introduction of a vaccine against 
HFMD remain. Co-administration studies are required to test for potential interactions 
with other vaccines included in the Expanded Program on Immunization, while 
further studies are merited to determine whether the vaccines are efficacious in 
children <6 months of age. The cross-protective efficacy of the EV-A71 vaccines is 
also uncertain. To date, the vaccines that have entered clinical evaluation have been 
based on locally dominant EV-A71 genotypes (C4 in China, B4 in Taiwan and B2 in 
Singapore). Although antibodies induced by a given EV-A71 strain exhibit cross-
neutralizing activity against other genotypes [90], this may not extend to all other EV-
A71 strains [91]. Moreover, vaccinating against EV-A71 tackles just one cause of 
HFMD. The EV-A71 vaccines showed no efficacy against HFMD caused by CV-A16 
or other serotypes during the recent phase III trials [87,88]. In the longer term, the 
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development of multivalent vaccines targeting EV-A71, CV-A16 and other 
enteroviruses associated with HFMD may be desirable. Preclinical studies of 
multivalent HFMD vaccines have commenced [92*]. 
 
 
Conclusion 
 
Focusing on a few examples of disease outbreaks, we have illustrated various 
clinical syndromes caused by non-polio enteroviruses, the complexity of their 
circulation dynamics and their capacity to spread rapidly.  
 
The mechanisms of emergence of outbreaks are not known and our understanding is 
limited by relatively weak surveillance systems, typically based on passive reporting 
by public health laboratory. A combination of virus-specific, population-level and 
other external factors is likely to be involved. The evolutionary dynamics of 
enteroviruses confer them with the capacity to experience rapid phenotypic changes, 
including transmissibility, antigenicity, virulence and tropism (i.e. spectrum of 
disease). At the population level, the number of non-immune individuals needs to be 
above a certain threshold for an outbreak to be triggered, and depends on the 
number of births and the serological status of the population. The immune status of 
the population at a given time is related, among others, to the previous exposure of 
that population to the same or a related virus, the cross-reactivity between different 
genogroups of a given serotype (and between different serotypes), and the decay of 
neutralizing antibodies over time. Finally, climatic and environmental variables seem 
to correlate with the peaks of incidence of disease (e.g. HFMD), which suggests that 
they might affect the survival of the virus outside the host or the efficiency of 
transmission, which might differ among serotypes depending on their transmission 
routes.  
 
Through genome sequencing, molecular epidemiology is helping to track the 
temporal and spatial circulation of different strains and determine their origin and 
geographical range. Large-scale genetic analyses have revealed the evolutionary 
and epidemiological dynamics of some serotypes. Distinct phylogenetic patterns 
have been described for different serotypes or even for different clades within a 
serotype (e.g. coxsackievirus B5 [93]). In some cases, ladder-like trees similar to 
influenza A have been obtained, consistent with continuous selection for new 
antigenic variants (e.g. echovirus 9 [94]). In other cases, co-circulation of several 
lineages has been observed, suggesting different selective forces or greater 
geographic isolation (e.g. echovirus 6 [95]). It has also been reported that peaks in 
incidence of some serotypes have been preceded by the emergence of recombinant 
groups (e.g. echovirus 9 [94]).  
 
Unfortunately, molecular analyses alone do not allow the biological mechanisms 
determining the patterns of circulation of individual serotypes to be elucidated, and in 
particular, the role of immunity remains poorly understood. However, molecular 
epidemiological studies combined with investigations of antigenic changes and 
serological surveys have the potential to provide novel insights towards better 
understanding the occurrence of outbreaks. This would also allow elucidation of the 
mechanisms acting across genogroups or serotypes, which could explain the 
periodic changes in predominant variants. For instance, one study with isolates of 
EV-A71 from Taiwan showed using phylogenetic analyses that every large outbreak 
between 1998 and 2008 was associated with a genotypic change, alternating 
between B and C (B1, C2, B4, C4, B5), and then using antigenic cartography 
showed that the predominant strain in every major outbreak was antigenically distinct 
from the predominant strain in the previous outbreak [96].  
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Understanding the contribution of strain- or serotype-specific and heterotypic 
population immunity to the patterns of circulation of non-polio enteroviruses may help 
explain and predict outbreaks of disease. Ultimately this may lead to improved 
vaccination strategies, including the selection of appropriate vaccine strains. 
 
 
Key points 
 
- Non-polio enteroviruses are an emerging cause of neurological diseases, 
predominantly arising as complications of mild, self-limiting infections. 
- The full spectrum of illnesses caused by individual serotypes remains 
unclear; e.g. EV-D68 has long been associated with respiratory diseases but 
is now suspected to also be responsible for acute flaccid myelitis. 
- Some enteroviruses spread worldwide very quickly, as illustrated by the 
pandemics of acute haemorrhagic conjunctivitis caused by CV-A24v, with a 
rapid turnover of genetic variants that emerge, spread globally and then 
vanish being replaced by new variants. 
- Patterns of circulation of individual serotypes, including changes in the 
predominant ones, are complex and how serotype-specific and heterotypic 
immunity affects those is not well understood; e.g. why have EV-A71 and CV-
A16 been replaced by CV-A6 as the main causative agent of HFMD in 
several countries in recent years? 
- Three inactivated candidate vaccines against EV-A71 have completed phase 
III trials in China and could be licensed soon. 
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Table 1. Human enterovirus serotypes. Updated from [2]. 
 
EV species Serotypes 
Species A Coxsackievirus A 2–8, 10, 12, 14, 16, Enterovirus 71, 76, 89–91, 114, 
119–121 
Species B Coxsackievirus A 9, Coxsackievirus B 1–6, Echovirus 1–7, 9, 11–21, 
24–27, 29–33, Enterovirus 69, 73–75, 77–88, 93, 97, 98, 100, 101, 
106, 107  
Species C Poliovirus 1–3, Coxsackievirus A 1, 11, 13, 17, 19–22, 24, Enterovirus 
95, 96, 99, 102, 104, 105, 109, 116–118 
Species D Enterovirus 68, 70, 94, 111 
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Table 2. Diseases caused by enteroviruses. Based on data from [2]. CV-A: 
coxsackievirus A; CV-B: coxsackievirus B; EV: enterovirus; E: echovirus; PV: 
poliovirus.  
 
Disease Serotypes commonly implicated 
CNS infections 
Acute flaccid paralysis 
Aseptic meningitis 
 
Encephalitis 
 
PVs, EV-A71 
PVs, CV-Bs, CV-A5, 7, 9, 16, E4, 6, 9, 11, 14, 
16, 25, 30, 31, EV-A71 
PVs, E6, 9, 17, 21, CV-A2, 9, CV-B1, EV-A71 
Heart disease 
(acute and chronic myocarditis, 
dilated cardiomyopathy) 
CV-Bs 
Eye infections 
Acute haemorrhagic conjunctivitis 
 
CV-A24v, EV-D70 
Skin rashes 
Hand-foot-and-mouth disease 
Herpangina 
 
CV-A 4–6, 9, 10, 16, CV-B2, 5, EV-A71 
CV-As, CV-Bs, E6, 9, 11, 16, 17, 22, 25, EV-A71 
Respiratory infections 
(common cold, rhinitis, 
pharyngitis, pneumonia, 
bronchiolitis and others) 
CV-As, CV-Bs, EV-D68, Es 
Muscle disease 
Epidemic pleurodynia 
Acute and chronic inflammatory 
myopathies 
 
CV-Bs, CV-A4, 6, 9, 10, E1, 6, 9, 16, 19 
CVs (in experimental animals) 
Pancreatitis CV-Bs 
Diarrhea CV-As, Es 
Undifferentiated febrile illness PVs, CV-Bs 
Neonatal infections 
(including prenatal, natal and 
postnatal infections)  
CV-Bs, Es 
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Figure 1. Schematic representation of the phylogenetic relationship between 
representative serotypes of the four species of human enteroviruses based 
on VP1 sequences reported in GenBank. A multiple sequence alignment was 
generated using Clustal Omega. A Neighbour-Joining tree was then created 
from this alignment, and visualised using FigTree v1.4.2 
(http://tree.bio.ed.ac.uk/software/figtree/). Branch lengths are not to scale. 
Accession numbers were as follows: CV-A6, AF081297; CV-A10, AF081300; 
CV-A24, AF081311; E6; AF081321; E11, AF081326; E30, AF081340; EV-68, 
AF081348; EV-71, JN168790; EV-70, D00820 (nucleotides 2425–3339); 
PV1, V01149 (nucleotides 2480–3385); and CV-A16, U05876 (nucleotides 
2446–3336). CV-A: coxsackievirus A; E: echovirus; EV: enterovirus; PV: 
poliovirus.  
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Figure 2. Number of annually reported echovirus 9 and coxsackievirus B4 detections 
in the United States. Based on data from [4].  
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